Evidence map›Paper›PMID 37639051›Full record

ArticleJournal of materials science. Materials in medicine2023

Enhanced therapeutic effects of mesenchymal stem cell-derived extracellular vesicles within chitosan hydrogel in the treatment of diabetic foot ulcers.

Shuangshuang Yang, Siyu Chen, Chengpeng Zhang, Jing Han, Chunyuan Lin, Xiaohui Zhao, Huizhen Guo, Yi Tan

Open access · goldAbstract read
In one paragraph

Article in Journal of materials science. Materials in medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Article
  6. HucMSCs-Derived Extracellular Vesicles Deliver RPS27A Protein to Manipulate the MDM2-P53 Axis and Ameliorate Neurological Dysfunction in Parkinson's Disease.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2025
    Article
  7. NcRNAs: a potential treatment for spinal cord injury.Frontiers in cellular neuroscience · 2025
    Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Shuangshuang YangQilu Cell Therapy Technology Co., Ltd, No.1758 Gangyuan Six Road, Ji'nan, Shandong, China.
Siyu ChenQilu Cell Therapy Technology Co., Ltd, No.1758 Gangyuan Six Road, Ji'nan, Shandong, China.
Chengpeng ZhangQilu Cell Therapy Technology Co., Ltd, No.1758 Gangyuan Six Road, Ji'nan, Shandong, China.
Jing HanQilu Cell Therapy Technology Co., Ltd, No.1758 Gangyuan Six Road, Ji'nan, Shandong, China.
Chunyuan LinQilu Cell Therapy Technology Co., Ltd, No.1758 Gangyuan Six Road, Ji'nan, Shandong, China.
Xiaohui ZhaoQilu Cell Therapy Technology Co., Ltd, No.1758 Gangyuan Six Road, Ji'nan, Shandong, China.
Huizhen GuoQilu Cell Therapy Technology Co., Ltd, No.1758 Gangyuan Six Road, Ji'nan, Shandong, China.
Yi TanQilu Cell Therapy Technology Co., Ltd, No.1758 Gangyuan Six Road, Ji'nan, Shandong, China. pkuty@126.com.
Cell Technology (China) · CN

Funding

Ministry of Science and Technology of the People's Republic of China 2021YFA1101502Natural Science Foundation of Shandong Province ZR2021QC202
6 · The paper itself

Abstract

Extracellular vesicles (EVs) derived from human umbilical cord mesenchymal stem cells (hUCMSCs) have emerged as promising candidates for cell-free therapy in various diseases, including chronic cutaneous wounds. However, the lack of standardized protocols for EVs' preparation and identification poses a significant challenge to their clinical application. Thus, the objective was to develop a safe and efficient method for the large-scale production of hUCMSC-derived EVs while establishing a comprehensive identification protocol encompassing morphology, particle size distribution, protein expression, and purity. This study observed that most of the EVs acquired through the protocol exhibited either a cup-shaped or round-shaped structure, with a median diameter of ~73.25 nm. The proportions of EVs positive for CD9, CD63, and CD81 were 37.5%, 38.6%, and 19.8%, respectively. To enhance their therapeutic potential in wound treatment, EVs were incorporated into chitosan hydrogel, forming chitosan hydrogel-EVs (CS-EVs). Furthermore, it was demonstrated that CS-EVs exhibited continuous release of EVs into the surrounding environment and, importantly, that the released EVs were internalized by human umbilical vein endothelial cells (HUVECs), resulting in significant enhancement of cell migration and angiogenesis. Additionally, in a rat model of diabetic foot ulcers, CS-EVs demonstrated a robust therapeutic effect in promoting wound healing. Following a 15-day treatment period, the group treated with CS-EVs demonstrated an impressive 93.3% wound closure ability, accompanied by a high degree of re-epithelialization. In contrast, the control group exhibited only a 71.5% reduction in wound size. In summary, this study offers solutions for the purification, characterization, and application of EVs in clinical wound treatment. These results not only offer fresh perspectives on the involvement of hUCMSC-derived EVs in wound healing but also introduce a non-invasive approach for applying EVs that holds practical significance in skin repair.

Indexed as

ChitosanDiabetes MellitusDiabetic FootExtracellular VesiclesMesenchymal Stem CellsAnimalsHumansHuman Umbilical Vein Endothelial CellsHydrogelsRatsChitosanHydrogels

Identifiers

PMID37639051
PMCPMC10462522
OpenAlexW4386209409

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.